Tumor-Infiltrating Lymphocytes: Infiltrating the Boundaries of Cancer Care in Solid Tumors Through a Managed Care Lens
This activity offers a fundamental understanding of the role of TIL therapy in solid tumors, including the mechanism of action, clinical evidence, toxicity management and best practices to support safe and efficacious use of TILs in both inpatient and outpatient settings. As the role of TIL therapy expands, managed care professionals and pharmacists must evaluate existing clinical protocols and the financial implications of TIL therapy. Approaches for managed care professionals to individualize therapeutic selections and coordinate comprehensive plans for the adoption of TILs into the treatment paradigms for various solid tumors will be discussed.
At the completion of this activity, participants will be able to:
- Examine emerging tumor-infiltrating lymphocytes (TILs) as a treatment option and their unique pharmacology and mechanisms of action.
- Distinguish opportunities for pharmacists to individualize patient care through management of adverse effects that may arise from TIL therapy.
- Identify value-based solutions for addressing the costs associated with TIL therapy.
Robin Lockhorst, PharmD, BCPS, BCOP
Avera Cancer Institute
This webinar is sponsored, developed, and presented by the sponsor. The content of this webinar and opinions expressed by the presenter are those of the sponsor or presenter and not of AMCP.